Physician profile
Jason S Levitz
NPI 1689783961
$18,531.16
in general payments reported to CMS, 2019-2025
77 companies · $3,222 in 2025
The $3,222 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,603 · 2020: $2,357 · 2021: $2,075 · 2022: $1,970 · 2023: $2,311 · 2024: $2,994 · 2025: $3,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,622 · Long Term Medical Supply Or Device Loan: $1,863 · Education: $41.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,622.16 |
| Long Term Medical Supply Or Device Loan | $1,863.04 |
| Education | $41.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,199.68 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,596.69 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,566.35 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Janssen Biotech, INC. | $986.89 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Merck Sharp & Dohme LLC | $781.61 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $716.52 | 2019-2025 | Jakafi |
| Daiichi Sankyo INC. | $698.12 | 2020-2025 | Enhertu, Vanflyta, Datroway |
| Seagen INC. | $606.92 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Amgen INC. | $602.41 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Glaxosmithkline, LLC. | $512.30 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Astellas Pharma US INC | $403.97 | 2019-2025 | Vyloy, Padcev |
| Genentech USA, INC. | $398.11 | 2019-2025 | Polivy, Lunsumio, Perjeta |
| Exelixis INC. | $391.12 | 2021-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $368.21 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $341.07 | 2020-2024 | Xpovio |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Levitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.